---
_id: '8244'
abstract:
- lang: eng
  text: Passive immunotherapy with monoclonal antibodies represents a cornerstone
    of human anticancer therapies, but has not been established in veterinary medicine
    yet. As the tumor-associated antigen EGFR (ErbB-1) is highly conserved between
    humans and dogs, and considering the effectiveness of the anti-EGFR antibody cetuximab
    in human clinical oncology, we present here a “caninized” version of this antibody,
    can225IgG, for comparative oncology studies. Variable region genes of 225, the
    murine precursor of cetuximab, were fused with canine constant heavy gamma and
    kappa chain genes, respectively, and transfected into Chinese hamster ovary (CHO)
    DUKX-B11 cells. Of note, 480 clones were screened and the best clones were selected
    according to productivity and highest specificity in EGFR-coated ELISA. Upon purification
    with Protein G, the recombinant cetuximab-like canine IgG was tested for integrity,
    correct assembly, and functionality. Specific binding to the surface of EGFR-overexpressing
    cells was assessed by flow cytometry and immunofluorescence; moreover, binding
    to canine mammary tissue was demonstrated by immunohistochemistry. In cell viability
    and proliferation assays, incubation with can225IgG led to significant tumor cell
    growth inhibition. Moreover, this antibody mediated significant tumor cell killing
    via phagocytosis in vitro. We thus present here, for the first time, the generation
    of a canine IgG antibody and its hypothetical structure. On the basis of its cetuximab-like
    binding site, on the one hand, and the expression of a 91% homologous EGFR molecule
    in canine cancer, on the other hand, this antibody may be a promising research
    compound to establish passive immunotherapy in dog patients with cancer.
article_processing_charge: No
article_type: original
author:
- first_name: J.
  full_name: Singer, J.
  last_name: Singer
- first_name: Judit
  full_name: Fazekas, Judit
  id: 36432834-F248-11E8-B48F-1D18A9856A87
  last_name: Fazekas
  orcid: 0000-0002-8777-3502
- first_name: W.
  full_name: Wang, W.
  last_name: Wang
- first_name: M.
  full_name: Weichselbaumer, M.
  last_name: Weichselbaumer
- first_name: M.
  full_name: Matz, M.
  last_name: Matz
- first_name: A.
  full_name: Mader, A.
  last_name: Mader
- first_name: W.
  full_name: Steinfellner, W.
  last_name: Steinfellner
- first_name: S.
  full_name: Meitz, S.
  last_name: Meitz
- first_name: D.
  full_name: Mechtcheriakova, D.
  last_name: Mechtcheriakova
- first_name: Y.
  full_name: Sobanov, Y.
  last_name: Sobanov
- first_name: M.
  full_name: Willmann, M.
  last_name: Willmann
- first_name: T.
  full_name: Stockner, T.
  last_name: Stockner
- first_name: E.
  full_name: Spillner, E.
  last_name: Spillner
- first_name: R.
  full_name: Kunert, R.
  last_name: Kunert
- first_name: E.
  full_name: Jensen-Jarolim, E.
  last_name: Jensen-Jarolim
citation:
  ama: Singer J, Singer J, Wang W, et al. Generation of a canine anti-EGFR (ErbB-1)
    antibody for passive immunotherapy in dog cancer patients. <i>Molecular Cancer
    Therapeutics</i>. 2014;13(7):1777-1790. doi:<a href="https://doi.org/10.1158/1535-7163.mct-13-0288">10.1158/1535-7163.mct-13-0288</a>
  apa: Singer, J., Singer, J., Wang, W., Weichselbaumer, M., Matz, M., Mader, A.,
    … Jensen-Jarolim, E. (2014). Generation of a canine anti-EGFR (ErbB-1) antibody
    for passive immunotherapy in dog cancer patients. <i>Molecular Cancer Therapeutics</i>.
    American Association for Cancer Research. <a href="https://doi.org/10.1158/1535-7163.mct-13-0288">https://doi.org/10.1158/1535-7163.mct-13-0288</a>
  chicago: Singer, J., Judit Singer, W. Wang, M. Weichselbaumer, M. Matz, A. Mader,
    W. Steinfellner, et al. “Generation of a Canine Anti-EGFR (ErbB-1) Antibody for
    Passive Immunotherapy in Dog Cancer Patients.” <i>Molecular Cancer Therapeutics</i>.
    American Association for Cancer Research, 2014. <a href="https://doi.org/10.1158/1535-7163.mct-13-0288">https://doi.org/10.1158/1535-7163.mct-13-0288</a>.
  ieee: J. Singer <i>et al.</i>, “Generation of a canine anti-EGFR (ErbB-1) antibody
    for passive immunotherapy in dog cancer patients,” <i>Molecular Cancer Therapeutics</i>,
    vol. 13, no. 7. American Association for Cancer Research, pp. 1777–1790, 2014.
  ista: Singer J, Singer J, Wang W, Weichselbaumer M, Matz M, Mader A, Steinfellner
    W, Meitz S, Mechtcheriakova D, Sobanov Y, Willmann M, Stockner T, Spillner E,
    Kunert R, Jensen-Jarolim E. 2014. Generation of a canine anti-EGFR (ErbB-1) antibody
    for passive immunotherapy in dog cancer patients. Molecular Cancer Therapeutics.
    13(7), 1777–1790.
  mla: Singer, J., et al. “Generation of a Canine Anti-EGFR (ErbB-1) Antibody for
    Passive Immunotherapy in Dog Cancer Patients.” <i>Molecular Cancer Therapeutics</i>,
    vol. 13, no. 7, American Association for Cancer Research, 2014, pp. 1777–90, doi:<a
    href="https://doi.org/10.1158/1535-7163.mct-13-0288">10.1158/1535-7163.mct-13-0288</a>.
  short: J. Singer, J. Singer, W. Wang, M. Weichselbaumer, M. Matz, A. Mader, W. Steinfellner,
    S. Meitz, D. Mechtcheriakova, Y. Sobanov, M. Willmann, T. Stockner, E. Spillner,
    R. Kunert, E. Jensen-Jarolim, Molecular Cancer Therapeutics 13 (2014) 1777–1790.
date_created: 2020-08-10T11:54:29Z
date_published: 2014-07-01T00:00:00Z
date_updated: 2021-01-12T08:17:42Z
day: '01'
doi: 10.1158/1535-7163.mct-13-0288
extern: '1'
intvolume: '        13'
issue: '7'
language:
- iso: eng
month: '07'
oa_version: None
page: 1777-1790
publication: Molecular Cancer Therapeutics
publication_identifier:
  issn:
  - 1535-7163
  - 1538-8514
publication_status: published
publisher: American Association for Cancer Research
quality_controlled: '1'
status: public
title: Generation of a canine anti-EGFR (ErbB-1) antibody for passive immunotherapy
  in dog cancer patients
type: journal_article
user_id: 2DF688A6-F248-11E8-B48F-1D18A9856A87
volume: 13
year: '2014'
...